{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[15,2,15,3],[16,2,16,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910488724503321"]
[null,null,"Titolo",null,"Essentials of tissue and cells banking / / George Galea, Marc Turner and Sharon Zahra (editors)"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-71621-X"]
[null,null,"Edizione",null,"[Second edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (288 pages)"]
[null,null,"Disciplina",null,"362.1783"]
[null,null,"Soggetti",null,"Tissue banks"]
[{"$nulls":4},"Procurement of organs, tissues, etc"]
[{"$nulls":4},"Preservation of organs, tissues, etc"]
[{"$nulls":4},"Bancs de teixits"]
[{"$nulls":4},"Conservació de teixits (Biologia)"]
[{"$nulls":4},"Conservació d'òrgans"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- 1 Live Donors of Tissue -- Abstract -- 1.1 Introduction -- 1.2 Regulation -- 1.3 Donor Identification -- 1.3.1 Femoral Head Donation -- 1.3.2 Amniotic Membrane Donation -- 1.4 Consent -- 1.5 Donor Selection: Evidence Base and General Considerations -- 1.6 Generic Contraindications -- 1.6.1 Transmissible Infections -- 1.6.2 Acute Infections -- 1.6.3 Risk of Transmission of Prion Diseases -- 1.6.4 Malignancy -- 1.7 Retrieval/Procurement -- 1.8 Summary -- References -- 2 Deceased Tissue Donors -- Abstract -- 2.1 Introduction -- 2.2 Deceased Tissue Donor Identification -- 2.3 The Law and the Role of the Family -- 2.4 Age Cut-Offs -- 2.5 Medical, Behavioural and Social Assessment -- 2.6 Blood Sampling and Haemodilution -- 2.7 Timing and Venue of Retrieval -- 2.8 Retrieval Process -- 2.9 Conclusion -- References -- 3 Banking and Use of Umbilical Cord Blood -- Abstract -- 3.1 Introduction -- 3.2 Donation Programmes -- 3.2.1 Collection Sites -- 3.2.2 Recruitment and Consent -- 3.2.3 Donor Elegibility -- 3.2.4 Collection Techniques -- 3.2.5 Donor Follow up -- 3.2.6 Non-Frozen Transportation -- 3.3 Umbilical Cord Blood Processing and Storage -- 3.3.1 Banking Structure and Resources -- 3.3.2 Reception and Process Acquisition -- "]
[{"$nulls":4},"3.3.3 Volume Reduction -- 3.3.4 Cryopreservation -- 3.3.5 Testing and Product Conformity -- 3.3.6 Inventory Management -- 3.4 Use of Umbilical Cord Blood for Transplantation -- 3.4.1 Selection Principles -- 3.4.2 Request for Shipping -- 3.4.3 Frozen Transportation -- 3.4.4 Thawing and Infusion -- 3.4.5 Transplantation Outcomes -- 3.5 Future Challenges for Umbilical Cord Blood Banking -- References -- 4 Ocular Tissue Banking -- Abstract -- 4.1 Eye Donation -- 4.2 Corneal Transplantation -- 4.3 Corneal Storage -- 4.4 Hypothermia -- 4.5 Organ Culture -- 4.6 Limbal Stem Cells."]
[{"$nulls":4},"4.7 Extending the Role of Eye Banks -- 4.8 Other Cell-Based Therapies for Ocular Disease -- References -- 5 Banking of Heart Valves -- Abstract -- 5.1 Introduction -- 5.2 Selection Criteria -- 5.3 Processing and Disinfection of Heart Valves -- 5.4 Quality Assurance of Heart Valves -- 5.5 Current Issues in Heart Valve Banking -- 5.5.1 Mechanical Properties of Valves -- 5.6 Decellularization -- 5.7 Vitrification -- 5.8 Matching of Valves -- 5.9 Centralised Supply -- 5.10 Conclusions -- References -- 6 Cryopreservation and Banking of Haematopoietic Progenitor Cells -- Abstract -- 6.1 Introduction -- 6.2 Transportation of HPC Product from the Collection Site to Stem Cell Laboratory -- 6.3 Receipt and Initial Storage of HPC Products -- 6.4 Preparation of HPC Products for Cryopreservation -- 6.5 Cryopreservation of HPC Products -- 6.6 Rate of Freezing -- 6.7 Storage of HPC Products -- 6.8 Transport of Frozen HPC Products -- 6.9 Further Processing Performed by Stem Cell Laboratories -- 6.9.1 Bone Marrow (HPC,M) Processing -- 6.9.2 Selection/Depletion -- 6.9.3 Campath in the Bag -- 6.10 Quality Control of the HPC Product -- 6.11 Quality Control Post Cryopreservation -- 6.12 Conclusion -- References -- 7 Storage, Processing and Preservation -- Abstract -- 7.1 Introduction -- 7.1.1 Tissue Replacement -- 7.1.2 Autologous Versus Allogeneic Grafts -- 7.1.3 Immunological Reponses to Tissue Allografts -- 7.2 Principles of Tissue Preservation -- 7.2.1 Preservation of Non Viable Tissue Grafts -- 7.2.1.1 Causes of Degradation -- 7.2.1.2 Reduction of Water Activity -- Freeze-Drying (Lyophilisation) -- Deep Freezing -- High Concentration Solutes -- 7.2.1.3 Cell Removal -- 7.2.2 Preservation of Viable Tissue Grafts -- 7.3 Principles of Disinfection and Sterilisation -- 7.3.1 Definitions -- 7.3.2 Disinfection Methods -- 7.3.2.1 Viable Tissues -- 7.3.2.2 Non-viable Tissues."]
[{"$nulls":4},"7.3.3 Sterilisation Methods -- 7.3.3.1 Physical Methods -- 7.3.3.2 Chemical Methods -- References -- 8 Cryopreservation in Tissue Banking -- Abstract -- 8.1 Introduction -- 8.2 Critical Impact of Ice Formation -- 8.3 The Role of Added Cryoprotectants -- 8.4 Sample Thawing -- 8.5 Spheroid and Organoid Cryopreservation -- 8.6 Toward the Cryopreservation of Organs and Biopsies -- 8.7 Quality Issues -- 8.8 Sterility, Handling and Contamination Issues -- 8.9 Conclusion -- References -- 9 Sterilisation by Irradiation -- Abstract -- 9.1 Introduction -- 9.2 Specificity of Radiation Sterilisation with Gamma Rays and Electron Beams -- 9.3 Dosimetry for Radiation Sterilisation -- 9.4 Mechanisms Involved in the Inactivation of Micro-organisms by Ionising Radiation -- 9.5 Radiation Resistance of Micro-organisms -- 9.6 Summary and Conclusions -- References -- 10 Screening the Tissue Donor for Infectious Agents -- Abstract -- 10.1 Introduction -- 10.2 Sample Quality -- 10.2.1 Living v. Deceased Donors -- 10.2.1.1 Donor Selection -- 10.2.1.2 Laboratory Screening -- 10.2.2 Haemodilution -- 10.2.3 Screening Targets -- 10.3 Range of Infectious Agents -- 10.3.1 Mandatory Screening -- 10.3.2 Additional/Selective Screening -- 10.3.3 Screening for Other Infectious Agents -- 10.4 Emerging Infectious Threats -- 10.5 Screening Strategy -- 10.5.1 Screening Algorithms -- 10.6 Screening Assays -- 10.6.1 Serological "]
[{"$nulls":4},"Screening Assays -- 10.6.2 Molecular Screening Assays -- 10.7 Residual Risk -- 10.7.1 Window Period -- 10.8 Conclusions -- References -- 11 Contamination in the Tissue Way -- Abstract -- 11.1 Introduction -- 11.1.1 Bacteria and Fungi -- 11.2 The Tissue Way, P.L.C. Petit [22] -- 11.2.1 Donor -- 11.2.2 Tissue Retrieval in mortuary (1) or operating theatre (2) -- 11.2.3 Transport -- 11.2.4 Tissue Establishment -- 11.2.5 Microbiology Laboratory -- 11.3 Specific Items."]
[{"$nulls":4},"11.4 Future -- References -- 12 Establishing a Quality System in a Tissue Establishment -- 12.1 Background -- 12.2 The History of Quality Management -- 12.3 Why a Quality Management System -- 12.4 Why Quality? -- 12.5 What is Quality? -- 12.6 Examples of Methods to Be Used in Quality -- 12.7 Available Standards and International Legal Documents -- 12.8 Setting Up a Quality System -- 12.9 Risk Management -- 12.10 Applying a Quality System to Your Activities -- 12.10.1 Where Do I Start? -- 12.11 Biovigilance -- 12.12 Quality Systems and IT -- 12.13 Data Protection -- 12.14 The Cost of Quality -- 12.14.1 The Cost of Quality Can Be Categorized into Four Categories -- 12.15 Role of Management and Quality Management Review -- 12.16 Conclusion -- References -- 13 IT System Requirements for Tissue and Cell Banking -- Abstract -- 13.1 Introduction -- 13.2 Why Introduce an IT System? -- 13.3 The Benefits of an IT System -- 13.4 What Are the Operational Requirements? -- 13.5 Developing the Operational Requirements Document (ORD) -- 13.5.1 Functional Requirements -- 13.5.2 Non-functional Requirements -- 13.6 Technology Solutions -- 13.7 Managing the Data -- 13.7.1 Barcodes -- 13.7.2 Radio Frequency Identification (RFID) -- 13.7.3 OCR/ICR/Touch Screens -- 13.7.4 Electronic System Interfaces -- 13.8 Database Management Technology -- 13.9 Selecting an IT System -- 13.10 Cost of an IT System -- 13.11 Implementing an IT System -- 13.11.1 Define Success -- 13.11.2 Set Priorities -- 13.11.3 Avoid Modifications -- 13.11.4 Prepare for Change -- 13.11.5 Gain Executive Support -- 13.11.6 People -- 13.12 Implementation Approach -- 13.13 System Validation -- 13.14 User Training -- 13.15 Managing an IT System -- 13.16 Conclusions -- References -- 14 Ethical and Regulatory Aspects of Cell and Tissue Banking -- Abstract -- 14.1 Introduction -- 14.2 Ethical Issues."]
[{"$nulls":4},"14.2.1 Donor Consent -- 14.2.1.1 Types of Consent -- 14.2.1.2 Capacity to Consent -- Saviour Siblings -- Cord Blood -- 14.2.1.3 Informed Consent -- 14.2.2 Voluntary Donation -- 14.2.3 Property Rights -- 14.2.3.1 Commercialisation -- 14.2.4 Confidentiality -- 14.2.5 Certification of Death -- 14.2.6 Just Access -- 14.2.7 Safety Issues -- 14.2.7.1 Infrastructure and Procedures -- 14.2.7.2 Healthcare Personnel -- 14.3 Societal Issues -- 14.3.1 Altruism -- 14.3.2 Education -- 14.3.3 Cross-Border Exchange -- 14.3.4 Trafficking -- 14.4 Regulatory Instruments -- 14.4.1 Donor Consent -- 14.4.2 Transplant Institutions -- 14.4.3 Data Protection -- 14.4.4 Training -- 14.5 Special Considerations for Cellular Therapies -- 14.5.1 Capacity to Consent -- 14.5.2 Limits of Certainty of Consent -- 14.5.3 Scope of Consent -- 14.5.4 Duration of Consent -- 14.5.5 Commercialisation -- 14.6 The Future -- 15 Human Embryonic Stem Cell Banking for Clinical Applications-20 Years from Their Isolation -- Abstract -- 15.1 Introduction -- 15.2 Human Embryonic Versus Induced Pluripotent Stem Cells as Clinical Source Material -- 15.3 Human Embryonic Stem Cell-Based Therapies -- 15.3.1 Currently Under Clinical Evaluation -- 15.3.2 Clinically Qualified Source Materials -- 15.4 Consensus Standards for Cell Banking -- 15.4.1 Ethics -- 15.4.2 Data Standardisation -- 15.5 Basic Scientific Developments "]
[{"$nulls":4},"Impacting on Quality Control and Safety -- 15.5.1 Genetic and Epigenetic Instability Affecting Lineage and Oncogenic Potential -- 15.6 Summary -- References -- Index."]